Clinical Trial Update: Study With Rituximab-Gemcitabine/Oxaliplatin in Relapsed Indolent Lymphoma [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/2 clinical trial evaluating Rituximab-Gemcitabine/Oxaliplatin in relapsed indolent non-Hodgkin lymphoma has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Indolent Non-hodgkin Lymphoma

Drugs mentioned

• Gemcitabine (Gemcitabine)
• OXALIPLATIN (Oxaliplatin)
• Rituximab (rituximab)

Snippet

Sponsor: German Low Grade Lymphoma Study Group | Conditions: Indolent Lymphoma | Phase 1, Phase 2 | Status: TERMINATED